Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Lighthouse, Verona Pharma, Manroy...

Mon, 09th Jul 2012 10:25

Shares in Lighthouse Group, the financial advice and wealth management group, plunged on Monday after the company proposed to cancel its listing on AIM. The group must receive approval from shareholders representing at least three-quarters of the company's shares for the cancellation to be approved. The firm will officially propose the cancellation at a general meeting on July 31st. If a cancellation is approved, it is expected it will take effect on August 8th. Verona Pharma, a biotechnology company focused on developing treatments for chronic respiratory diseases, has begun a new trial with its lead drug candidate, RPL554. The trial is designed to test the anti-inflammatory properties of RPL554 in healthy subjects in relation to chronic obstructive pulmonary disease. The trial is a randomised, double-blind, placebo-controlled study that will enrol 24 subjects and is expected to finish around year-end. The trial is the first that is designed to evaluate specifically the anti-inflammatory properties of RPL554 in human subjects.Manroy, a UK defence contractor, has secured a new £4.1m contract with an existing export customer. Under the agreement Manroy will supply a variety of ancillary equipment which will be delivered around three months after the award of Manroy's export licence from the UK government, meaning the income generated from the contract will appear in the results for the next financial year. Forbidden Technologies, an owner and developer of the FORscene cloud video platform, has announced that Lion Television is using FORscene as its logging and rough cut editing platform at its facilities in Scotland. The contract follows a long-standing relationship between the two firms, with Lion Television a long-time user of FORscene at its London facility. Asset tracking and location identification technology firm Ubisense has added car manufacturer Hyundai Kia to its customer list, expanding its footprint in Asia. Hyundai Kia has deployed Ubisense's real-time locating systems (RTLS) solution on its assembly line manufacturing plant in South Korea. "The addition of Hyundai Kia significantly strengthens our position in Asia and highlights the increasing traction our RTLS product is gaining in the automotive market," the firm said. DDD Group, a three-dimensional (3D) solutions company, has launched the Yabazam 3D movie app for Samsung Smart TVs with 3D capability. The free-to-download application streams 3D movie trailers from the growing collection of 3D movies available at Yabazam.com. Later this month customers will be able to download full length 3D movies for a pay-per-view fee. The firm said the new 3D app expands Yabazam's reach to a much wider audience and gives the owners of Samsung Smart TVs with 3D capabilities access to an even greater range of 3D content.Tristel, a manufacturer of infection prevention, contamination control and specialist hygiene products, has made its first major shipment of sterile-packed disinfectant products to Basan Germany as part of the supply and distribution agreement with Basan which became effective on April 1st of this year. The shipment provides Basan with its initial stocking inventory of Tristel disinfectant products for use in the clean rooms of pharmaceutical manufacturers, medical device manufacturers, life sciences and biotech companies. "This shipment of all the sterile-packed product lines in our Crystel range marks the end of a long process of mobilisation and the beginning of our thrust into the global pharmaceutical and biotechnology market," the firm said. RAM Active Media, the media company specialising in pumping adverts and content to shopping centres and trains, has bagged a contract for the Stratford shopping centre in East London. The group's subsidiary, RAM Vision, has signed a capital sale and advertising sales contract with property owners CEPF Chariot and asset manager Catalyst Capital for the Stratford Centre, London. RAM Vision will source and install a large format landscape video screen within the Stratford Centre's main central square and manage a five-year contract for broadcasting advertising sales, scheduling and content. The Stratford Centre has recently benefited from a strong increase in custom and now accounts for an annual footfall in excess of 24m. The contract will deliver immediate revenue enhancement. Targeted Internet advertising technology company Phorm has begun commercial activities in Turkey following a previously announced agreement with an Internet service provider (ISP) in the region. The company, which has been dogged by complaints from Internet privacy campaigners during its history, has installed its system within the network of Turkish ISP, TTNET, which has around six million Turkish broadband lines. The firm is in the process of sending opt-in invitations to TTNET's subscribers and said it has been "delighted" with the results, which are now above its expectations. Commercial activities have begun and it is now serving advertisements using its system. Camco International, a global developer of clean energy projects and solutions to reduce greenhouse gas emissions, has appointed Jonathan Marren as Chief Financial Officer with immediate effect. Marren was most recently Deputy Head of Corporate Finance at Singer Capital Markets, prior to which he was at Peel Hunt between 2000 and 2010, where he was a Director in the Corporate Department with responsibility for their new energy and clean tech franchise. He acted as an advisor to Camco at both Singer Capital Markets and previously at Peel Hunt. Acting Chairman Jeff Kenna described Marren's experience as "extremely valuable". Telit, a leading machine-to-machine wireless technology company, has said that it expects its unaudited revenues in the first half of 2012 to be around $99m, an increase of 22% over revenues in the same period the previous year ($81.1m). Net debt at June 30th is expected to be around $1.0m (December 31st 2011: net cash $0.5m). Earlier this year Telit launched its managed services, under which the company initiated pilots with more than 80 customers. The company estimates that the pilot customers alone represent a potential market of more than one million annual subscriptions. A number of the pilot customers have already become fully-fledged commercial customers, the firm said. NR
More News
13 Jan 2020 11:08

Verona Pharma shares surge after results from latest study

(Sharecast News) - Respiratory disease-focussed biopharmaceuticals company Verona Pharma announced positive top-line data from a four week, 416 patient phase 2b dose-ranging study evaluating nebulised ensifentrine or placebo as an add-on treatment to 'Spiriva Respimat', or tiotropium, which is a long acting anti-muscarinic bronchodilator, in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).

Read more
13 Jan 2020 10:34

UK WINNERS & LOSERS SUMMARY: Spirent Up After Lifting Profit Guidance

UK WINNERS & LOSERS SUMMARY: Spirent Up After Lifting Profit Guidance

Read more
13 Jan 2020 07:56

Verona Pharma Says Ensifentrine Study Shows Positive Results

Verona Pharma Says Ensifentrine Study Shows Positive Results

Read more
5 Nov 2019 11:29

Verona Pharma losses widen as it pours resources into ensifentrine

(Sharecast News) - Biopharmaceutical company Verona Pharma updated the market on its operations and finances for the three and nine months ended 30 September on Tuesday, highlighting positive results from the second part of its phase 2 study of the dry powder inhaler formulation of 'ensifentrine' in chronic obstructive pulmonary disorder (COPD), delivered by handheld inhaler over one week of twice-daily treatment.

Read more
5 Nov 2019 10:38

UK WINNERS & LOSERS SUMMARY: AB Foods Rises As Primark Adds US Stores

UK WINNERS & LOSERS SUMMARY: AB Foods Rises As Primark Adds US Stores

Read more
5 Nov 2019 10:15

Verona Pharma Third Quarter Loss Widens On Research & Development

Verona Pharma Third Quarter Loss Widens On Research & Development

Read more
29 Oct 2019 15:30

Inland Homes snaps up 50% stake in Cheshunt Lakeside Development

(Sharecast News) - Inland Homes on Tuesday acquired a 50% interest in joint-venture partner Cheshunt Lakeside Developments Limited that was held by CPC Group Limited.

Read more
6 Aug 2019 12:01

Verona Pharma Loss Widens In First Half On Clinical Trial Expenses

(Alliance News) - Verona Pharma PLC on Tuesday said its loss widened in the second quarter and the first half of 2019 as it progressed on clinical trials of Ensifentrine, used for the treatment of

Read more
5 Aug 2019 10:42

WINNERS & LOSERS SUMMARY: Risk-Off Trade Sends Gold Miners Higher

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - up 3.1%. The Mexican gold miner rose as the price of

Read more
5 Aug 2019 09:44

Verona Pharma Shares Jump 15% On Positive Ensifentrine Study Results

(Alliance News) - Verona Pharma PLC on Monday reported positive second phase test data for a dry powder inhaler formulation of its lead development product ensifentrine.The stock was 15% in

Read more
25 Jun 2019 15:31

Verona Pharma strengthens clinical team ahead of next round of trials

(Sharecast News) - Respiratory-focussed biopharmaceutical company Verona Pharma announced two senior appointments to its clinical team on Tuesday.

Read more
29 May 2019 16:23

Director dealings: Piers Morgan's spouse ups stake in Verona Pharma

(Sharecast News) - Verona Pharma revealed on Wednesday that chief financial officer Piers Morgan's wife Kayt Morgan had acquired 33,802 ordinary shares in the AIM-listed biotechnology outfit.

Read more
7 May 2019 14:41

Verona Pharma announces next study of nebulised ensifentrine

(Sharecast News) - Clinical-stage biopharmaceutical company Verona Pharma announced the initiation of a phase 2b dose-ranging study evaluating nebulised ensifentrine (RPL554) added on to a long-acting bronchodilator in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) on Tuesday.

Read more
9 Apr 2019 15:25

Verona Pharma Gets EU Patent For COPD Clinical Candidate Ensifentrine

LONDON (Alliance News) - Verona Pharma PLC on Tuesday said it secured a key patent from the European Patent Office relating to its lead development candidate, ensifentrine.The clinical that

Read more
9 Apr 2019 08:23

Verona Pharma gets another European patent on ensifentrine

(Sharecast News) - Respiratory disease-focussed clinical stage biopharmaceutical company Verona Pharma announced on Tuesday that the European Patent Office had granted an additional key patent relating to its lead development candidate, 'ensifentrine'.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.